- Home
- OPTN
OPTN
OptiNose Inc.
as 01-17-2025 4:00pm EST
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | YARDLEY |
| Market Cap: | 78.4M | IPO Year: | 2017 |
| Target Price: | $16.67 | AVG Volume (30 days): | 60.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.82 - $31.50 | Next Earning Date: | 03-06-2025 |
| Revenue: | $75,672,000 | Revenue Growth: | 5.13% |
| Revenue Growth (this year): | 13.42% | Revenue Growth (next year): | 38.54% |
Stock Insider Trading Activity of OptiNose Inc. (OPTN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Marino Michael F III | OPTN | Chief Legal Officer & Corp Sec | Dec 17 '24 | Sell | $0.44 | 3,050 | $1,342.00 | 544,188 | |
| Mahmoud Ramy A | OPTN | Chief Executive Officer | Dec 17 '24 | Sell | $0.44 | 4,614 | $2,030.16 | 1,197,483 |
Latest OptiNose Inc. News
OPTN Breaking Stock News: Dive into OPTN Ticker-Specific Updates for Smart Investing
TipRanks
2 days ago
Optinose price target adjusted for stock split at Lake Street
GlobeNewswire
4 days ago
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
GlobeNewswire
24 days ago
Optinose Announces 1-for-15 Reverse Stock Split
GlobeNewswire
2 months ago
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
Simply Wall St.
2 months ago
OptiNose, Inc. (NASDAQ:OPTN) Just Reported, And Analysts Assigned A US$3.50 Price Target
Simply Wall St.
2 months ago
OptiNose Third Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.083 loss in 3Q 2023)
GuruFocus.com
2 months ago
OptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised Guidance
Thomson Reuters StreetEvents
2 months ago
Q3 2024 OptiNose Inc Earnings Call
Compare OPTN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OPTN OptiNose Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.